BGM and CGM Report Probes the 14530 million Size, Share, Growth Report and Future Analysis by 2033

Key Insights

The global blood glucose monitoring (BGM) and continuous glucose monitoring (CGM) market, valued at $14.53 billion in 2025, is projected to experience robust growth, driven by rising prevalence of diabetes, increasing geriatric population, and advancements in technology leading to more accurate and user-friendly devices. The market's Compound Annual Growth Rate (CAGR) of 9.8% from 2019 to 2033 indicates a significant expansion, particularly in the CGM segment. This segment's growth is fuelled by the advantages of continuous data monitoring, enabling proactive diabetes management and improved patient outcomes. While BGM remains a significant market segment due to its cost-effectiveness and widespread accessibility, the increasing adoption of CGMs in both hospital and household settings is expected to accelerate the overall market growth. Factors such as the increasing affordability of CGM systems and the rising awareness about the benefits of continuous glucose monitoring are also contributing to the shift toward CGM adoption. However, the market faces challenges such as high costs associated with CGM devices and potential sensor inaccuracies, which may limit their widespread adoption in certain regions. Nevertheless, continuous technological innovation and the development of more accurate, reliable, and affordable devices are expected to mitigate these restraints and fuel the market's sustained growth over the forecast period.

The competitive landscape is characterized by the presence of both established players like Abbott, Roche, and Medtronic, and emerging companies focused on innovation and affordability. The geographic distribution reveals strong growth potential across various regions, with North America and Europe currently dominating the market due to higher healthcare spending and advanced medical infrastructure. However, rapidly developing economies in Asia-Pacific, particularly China and India, are expected to witness significant growth in the coming years, driven by rising diabetes prevalence and increased healthcare investments. This necessitates a strategic approach by market players focusing on region-specific needs and adapting their product portfolio and marketing strategies accordingly to capitalize on the diverse market opportunities.

BGM and CGM Trends

The global blood glucose monitoring (BGM) and continuous glucose monitoring (CGM) market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. Over the study period (2019-2033), the market has witnessed a substantial expansion, with projections indicating continued robust growth throughout the forecast period (2025-2033). By the estimated year 2025, the combined market value of BGM and CGM is expected to surpass several billion USD, a testament to the escalating demand for effective diabetes management solutions. This growth is fueled by several factors, including technological advancements leading to more accurate, user-friendly devices; rising awareness about diabetes and its complications; and an increasing focus on preventative healthcare. The market is witnessing a gradual shift from traditional BGM towards CGM, reflecting the latter's ability to provide real-time glucose data and improve diabetes management outcomes. This transition, however, is influenced by factors like cost and accessibility, particularly in developing nations. Key players in the market are actively engaging in research and development to improve the accuracy, affordability, and convenience of both BGM and CGM systems, fostering market expansion and shaping future trends. The integration of advanced technologies like artificial intelligence and machine learning is further enhancing the capabilities of these devices, paving the way for personalized diabetes management strategies. The competitive landscape is dynamic, with both established players and emerging companies vying for market share, leading to continuous innovation and product diversification. This competitive pressure contributes to improving the overall quality and affordability of BGM and CGM devices for patients globally.

Driving Forces: What's Propelling the BGM and CGM Market?

Several key factors are propelling the growth of the BGM and CGM market. The escalating prevalence of diabetes, both type 1 and type 2, globally is a primary driver. This increase necessitates the consistent monitoring of blood glucose levels, boosting the demand for both BGM and CGM devices. Furthermore, technological advancements in sensor technology, data analytics, and device miniaturization have resulted in more accurate, user-friendly, and convenient devices, attracting a wider user base. The growing awareness among patients and healthcare professionals regarding the benefits of continuous glucose monitoring for better diabetes management is another significant driving force. CGM systems offer real-time glucose data, enabling proactive adjustments to insulin therapy and lifestyle interventions, ultimately improving glycemic control and reducing the risk of diabetes-related complications. Moreover, favorable regulatory environments and increasing insurance coverage for BGM and CGM devices are contributing to market expansion, particularly in developed economies. Finally, the rising adoption of remote patient monitoring (RPM) and telehealth solutions further supports the market's growth by facilitating efficient data collection and personalized diabetes management, even outside the traditional clinical setting.

Challenges and Restraints in BGM and CGM

Despite the significant market growth, several challenges and restraints hinder the widespread adoption of BGM and CGM technologies. The high cost of CGM systems remains a major barrier, limiting accessibility for many patients, especially in low- and middle-income countries. The need for regular calibration and potential sensor inaccuracies can impact the reliability and usability of CGM devices. Furthermore, the complexity of using CGM systems and the requirement for adequate training and education for patients can pose challenges to widespread adoption. The risk of hypoglycemia and hyperglycemia, despite the use of these monitoring devices, continues to be a concern and requires careful management. In addition, concerns regarding data privacy and security associated with the collection and transmission of patient glucose data need to be addressed effectively to ensure patient trust and confidence. Regulatory hurdles and reimbursement policies in different countries can also impact market penetration. Finally, the lack of sufficient awareness about the benefits of CGM in certain regions, particularly in developing countries, can also limit market growth.

Key Region or Country & Segment to Dominate the Market

• North America Dominance: North America is expected to hold a significant share of the global BGM and CGM market throughout the forecast period. This dominance stems from high diabetes prevalence, advanced healthcare infrastructure, and greater access to sophisticated technology. The region’s robust healthcare system, coupled with increased insurance coverage for diabetes management tools, fuels strong demand. High disposable income and early adoption of cutting-edge medical technologies also contribute to this dominance.

• Europe's Strong Growth: Europe follows closely behind North America, representing a substantial market for both BGM and CGM devices. Factors such as a growing diabetic population, expanding healthcare infrastructure, and increasing government initiatives promoting diabetes management contribute to Europe's significant market share. However, variations in reimbursement policies and healthcare systems across different European countries may present some challenges to market uniformity.

• Asia-Pacific's Emerging Potential: The Asia-Pacific region exhibits tremendous growth potential, driven by the rapidly increasing prevalence of diabetes across several countries. Rising healthcare expenditures, expanding middle-class populations, and increasing awareness about diabetes management are key factors propelling this growth. However, variations in income levels and healthcare access across different countries within the region create diverse market dynamics.

• CGM Segment's Accelerated Growth: The CGM segment is poised for accelerated growth compared to the BGM segment. While BGM continues to be widely used, the increasing demand for continuous, real-time glucose monitoring is driving the preference for CGM systems. This shift is primarily driven by the potential of CGM to improve diabetes management outcomes, reduce the risk of complications, and enhance patient quality of life.

• Household Application Dominance: The household application segment holds a dominant share within the overall market, reflecting the rising trend of self-management of diabetes at home. The increasing availability of user-friendly, portable BGM and CGM devices enhances the feasibility of home-based glucose monitoring, particularly for patients with type 1 diabetes.

In summary, the North American and European markets are established leaders due to their advanced healthcare systems and higher per capita income levels. However, the Asia-Pacific region shows considerable promise due to its expanding middle class and increasing prevalence of diabetes. The CGM segment and household applications represent the most rapidly expanding parts of the market, propelled by technological advancements and the increasing desire for improved self-management capabilities among patients.

Growth Catalysts in BGM and CGM Industry

The BGM and CGM industry is experiencing rapid growth driven by several key catalysts. Technological advancements, such as the development of smaller, more accurate, and easier-to-use devices, are making these technologies more accessible and appealing to a broader range of patients. The rising prevalence of diabetes, coupled with increasing awareness of the importance of blood glucose monitoring, continues to fuel demand. Furthermore, favorable regulatory environments and insurance coverage in various countries are facilitating market penetration and enabling more patients to access these essential tools for diabetes management.

Leading Players in the BGM and CGM Market

• Abbott
• Dexcom (Dexcom)
• Roche (Roche)
• Lifescan (Lifescan)
• Ascensia (Ascensia)
• Medtronic (Medtronic)
• ARKRAY
• Sinocare
• I-SENS
• Terumo
• B. Braun
• Acon
• Yicheng
• Omron
• SD Biosensor
• 77 Elektronika
• Yuwell
• Osang Healthcare
• AgaMatrix
• Senseonics Holdings

Significant Developments in BGM and CGM Sector

• 2020: Abbott launches FreeStyle Libre 2 system with improved accuracy and longer sensor lifespan.
• 2021: Dexcom receives FDA approval for its G6 CGM system with extended wear time.
• 2022: Roche expands its Accu-Chek portfolio with new features and improved connectivity.
• 2023: Several companies announce partnerships to integrate CGM data with insulin pump systems for improved automated insulin delivery (AID).
• Ongoing: Continuous research and development focused on improving sensor technology, enhancing data analytics capabilities, and developing minimally invasive CGM systems.

Comprehensive Coverage BGM and CGM Report

This report provides a comprehensive analysis of the BGM and CGM market, covering market size and growth projections, key drivers and restraints, competitive landscape, and future trends. It includes detailed information on leading players, their strategies, and recent developments in the industry. The report also offers insights into various market segments, including by type (BGM, CGM), application (household, hospital, other), and geographic regions. It serves as a valuable resource for companies operating in the BGM and CGM industry, investors seeking market opportunities, and healthcare professionals interested in the latest advancements in diabetes management.

BGM and CGM Segmentation

• 1. Type
  • 1.1. BGM
  • 1.2. CGM
• 2. Application
  • 2.1. Household
  • 2.2. Hospital
  • 2.3. Other

BGM and CGM Segmentation By Geography

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific